Photodynamic therapy-generated tumor cell lysates with CpG-oligodeoxynucleotide enhance immunotherapy efficacy in human papillomavirus 16 (E6/E7) immortalized tumor cells

Cancer Science

Volumn 98, Issue 5, 2007, Pages 747-752

  Bae, Su Mi ^a   Kim, Yong Wan ^a   Kwak, Sun Young ^a   Kim, Yong Wook ^a   Ro, Duck Yeong ^a   Shin, Jong Chul ^a   Park, Choong Hak ^b   Han, Sei Jun ^c   Oh, Chung Hun ^d   Kim, Chong Kook ^e   Ahn, Woong Shick ^a  

^a The Catholic University of Korea   (South Korea)

^b Dankook University   (South Korea)

^c Chosun University   (South Korea)

^d Dankook University   (South Korea)

^e Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; HEAT SHOCK PROTEIN 70; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; PHOTOSENSITIZING AGENT; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL IMMORTALIZATION; CELL LYSATE; CELLULAR IMMUNITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HELPER CELL; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR IMMUNITY;

ANIMALS; CANCER VACCINES; CELL EXTRACTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOTOXICITY TESTS, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HSP72 HEAT-SHOCK PROTEINS; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; INTERFERON TYPE II; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; OLIGODEOXYRIBONUCLEOTIDES; PHOTOCHEMOTHERAPY; T-LYMPHOCYTES, CYTOTOXIC; TUMOR NECROSIS FACTOR-ALPHA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34147147412     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00447.x     Document Type: Article

References (42)

1. Dougherty TJ. An update on photodynamic therapy applications. J Clin Laser Med Surg 2002; 20: 3-7.
2. Ackroyd R, Kelty C, Brown N, Reed M. The history of photodetection and photodynamic therapy. Photochem Photobiol 2001; 74: 656-69.
3. Yuan J, Mahama-Relue PA, Fournier RL, Hampton JA. Predictions of mathematical models of tissue oxygenation and generation of singlet oxygen during photodynamic therapy. Radiat Res 1997; 148: 386-94.
4. Korbelik M. Role of Toll-like receptors in photodynamic therapy-elicited host response. Proc SPIE 2004; 5319: 87-95.
5. Dougherty TJ, Gomer CJ, Henderson BW et al. Photodynamic therapy. J Natl Cancer Inst 1998; 90: 889-05.
6. Korbelik M, Sun J. Photodynamic therapy-generated vaccine for cancer therapy. Cancer Immunol Immunother 2006; 55: 900-9.
7. Gollnick SO, Vaughan L, Henderson BW. Generation of effective antitumor vaccines using photodynamic therapy. Cancer Res 2002; 62: 1604-8.
8. Ferrario A, von Tiehl KF, Rucker N, Schwarz MA, Gill PS, Gomer CJ. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res 2000; 60: 4066-9.
9. Ferrario A, Chantrain CF, von Tiehl K et al. The matrix metalloproteinase inhibitor prinomastat enhances photodynamic therapy responsiveness in a mouse tumor model. Cancer Res 2004; 64: 2328-32.
10. Krosl G, Korbelik M, Krosl J, Dougherty GJ. Potentiation of photodynamic therapy-elicited antitumor response by localized treatment with granulocyte-macrophage colony-stimulating factor. Cancer Res 1996; 56: 3281-6.
11. Jalili A, Makowski M, Switaj T et al. Effective photoimmunotherapy of murine colon carcinoma induced by the combination of photodynamic therapy and dendritic cells. Clin Cancer Res 2004; 10: 4498-08.
12. Korbelik M, Sun J, Naraparaju VR, Yamamoto N. Eradication of solid cancers by photodynamic therapy combined with dendritic cell-based adoptive immunotherapy. Cancer Res Proc 1999; 40: 86.
13. Kline JN, Krieg AM. CpG oligodeoxynucleotides. Prog Respir Res 2001; 31: 229-32.
14. Kim TY, Myoung HJ, Kim JH et al. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: Involvement of CD4+ and CD8+ T cells in protection. Cancer Res 2002; 62: 7234-40.
15. Horner AA, Raz E. Immunostimulatory sequence oligodeoxynucleotide-based vaccination and immunomodulation: Two unique but complementary strategies for the treatment of allergic diseases. J Allergy Clin Immunol 2002; 110: 706-12.
16. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon γ. Proc Natl Acad Sci USA 1996; 93: 2879-83.
17. Krieg AM, Yi AK, Matson S et al. CpG motifs in bacterial DNA trigger direct B cell activation. Nature 1995; 374: 546-9.
18. Ballas ZK, Rasmussen WL, Krieg AM. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 1996; 157: 1840-5.
19. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV. CpG oligonucleotides act as adjuvants that switch on T helper (Th1) immunity. J Exp Med 1997; 186: 1623-31.
20. Roman M, Martin-Orozco E, Goodman JS et al. Immunostimylatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 1997; 3: 849-54.
21. Warren TL, Bhatia SK, Acosta AM et al. APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells. J Immunol 2000; 165: 6244-51.
22. Davis HL, Weeranta R, Waldschmidt TJ, Tygrett L, Schorr J, Krieg AM. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 1998; 160: 870-6.
23. Kline JN, Waldschmidt TJ, Businga TR et al. Modulation of airway inflammation against asthma by CpG oligonucleotides in a murine model of asthma. J Immunol 1998; 160: 2555-9.
24. Gallichan WS, Woolstencroft RN, Guarasci T, McCluskie MJ, Davis HL, Rosenthal KL. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J Immunol 2001; 166: 3451-7.
25. Uzdensky AB, Dergacheva OY, Zhavoronkova AA, Reshetnikov AV, Ponomarev GV. Photodynamic effect of novel chlorine e6 derivatives on a single nerve cell. Life Sci 2004; 74: 2185-97.
26. Bodey B, Bodey B Jr, Siegel SE, Kaiser HE. Failure of cancer vaccines: the significant limitations of their approach to immunotherapy. Anticancer Res 2000; 20: 2665-76.
27. Suzuki Y, Wakita D, Chamoto K et al. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity. Cancer Res 2004; 64: 8754-60.
28. Brummel R, Lenert P. Activation of marginal zone B cells from lupus mice with type A (D) CpG-oligodeoxynucleotides. J Immunol 2005; 174: 2429-34.
29. Gramzinski RA, Doolan DL, Sedegah M, Davis HL, Krieg AM, Hoffman SL. Interleukin-12- and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice. Infect Immun 2001; 69: 1643-9.
30. Krieg AM. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr Oncol Re 2004; 6: 88-95.
31. Vasilakos JP, Smith RM, Gibson SJ et al. Adjuvant activities of immune response modifier R-848: Comparison with CpG ODN. Cell Immunol 2000; 204: 64-74.
32. Korbelik M, Sun J, Cecic I. Photodynamic therapy-induced cell surface expression and release of heat shock proteins: Relevance for tumor response. Cancer Res 2005; 65: 1018-26.
33. Kovarik J, Bozzotti P, Tougne C et al. Adjuvant effects of CpG oligodeoxynucleotides on responses against T-independent type 2 antigens. Immunology 2001; 102: 67-76.
34. Wang XS, Sheng Z, Ruan YB, Guang Y, Yang ML. CpG oligodeoxynucleotides inhibit tumor growth and reverse the immunosuppression caused by the therapy with 5-fluorouracil in murine hepatoma. World J Gastroenterol 2005; 11: 1220-4.
35. Tewary P, Sukumaran B, Saxena S, Madhubala R. Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen. Vaccine 2004; 22: 3053-60.
36. McCluskie MJ, Davis HL. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol 1998; 161: 4463-6.
37. Wild J, Grusby MJ, Schirmbeck R, Reimann J. Priming MHC-I-restricted cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD4+ T cell dependent. J Immunol 1999; 163: 1880-7.
38. Spies B, Hocrhrein H, Vabulas M et al. Vaccination with plasmid DNA activates dendritic cells via Toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice. J Immunol 2003; 171: 5908-12.
39. Stern AS, Magram J, Presky DH. Interleukin-12 an integral cytokine in the immune response. Life Sci 1996; 58: 639-54.
40. Bhattacharyya S, Singla R, Dey AB, Prasad HK. Dichotomy of cytokine profiles in patients and high-risk healthy subjects exposed to tuberculosis. Infect Immun 1999; 67: 5597-03.
41. Shams H, Wizel B, Weis SE, Samten B, Barnes PF. Contribution of CD8(+) T cells to gamma interferon production in human tuberculosis. Infect Immun 2001; 69: 3497-01.
42. Wu Y, Wan T, Zhou X et al. Hsp70-like protein 1 fusion protein enhances induction of carcinoembryonic antigen-specific CD8+ CTL response by dendritic cell vaccine. Cancer Res 2005; 65: 4947-54.